A fully automated microparticle enzyme immunoassay (EIA), lMx Core, was developed for the detection of antibody against hepatitis B core antigen (anti-HBc). IMx Core sensitivity was less than 0.5 Paul Ehrlich Institut units per ml and was greater than that of the commercial radioimmunoassay (RIA) or EIA, Corab and Corzyme, respectively. Specimens from blood donors and diagnostic and hospital patients, which included individuals with a variety of infectious and immune diseases, were tested in parallel by the IMx Core and EIA. Overall agreement of 99.1% (4,797 of 4,841) was obtained. Prevalence of anti-HBc tested by lMx Core ranged from 1.2% in volunteer blood donors to 9.1% in hospital laboratories. Discordant specimens reactive by IMx Core but negative by Corzyme or Corab resulted from the increased sensitivity of the IMx Core assay, since other hepatitis B markers were usually present. However, most discordant specimens were positive by the EIA or RIA but negative by IMx Core. No other hepatitis B markers could be detected in these discordants, and after addition of reducing agent, these specimens also became negative by EIA or RIA. In clinical trials, 30% (14 of 47) of volunteer blood donors and 8% (9 of 119) of hospital patients testing repeatedly reactive by the EIA had reduction-sensitive (unspecific) anti-HBc reactivity. The reducing agent, dithiothreitol, was added to each specimen automatically in the TMx assay to eliminate these unspecific reactions without significantly affecting anti-HBc reactivity resulting from hepatitis B virus infection as judged by the correlation with other hepatitis B markers.
Antibody to hepatitis B core antigen (anti-HBc) is one of the earliest serological markers during hepatitis B virus (HBV) infection and is generally present during acute, convalescent, and chronic phases of the disease (4, 17) . Anti-HBc usually persists for many years after infection and may be the only marker of previous exposure, since antibody to hepatitis B surface antigen (anti-HBs) may wane with time (14) .
Since 1986, tests for anti-HBc have been widely used in the United States for screening blood donors, since epidemiological studies have shown that anti-HBc could serve as a surrogate marker for non-A, non-B hepatitis (6, 16) . Several investigators have observed low-level anti-HBc test results near the assay cutoff in healthy blood donors testing negative for hepatitis B surface antigen (HBsAg) and have suggested that most of these results were due to poor specificity of the current, commercial immunoassays (1, 2, 13) .
Several lines of evidence indicate that many low-level anti-HBc-reactive specimens are reproducible and have a factor which specifically binds hepatitis B core antigen (HBcAg). Staller et al. (15) showed that 92% of low-level reactive specimens were confirmed by neutralization with HBcAg derived from recombinant DNA in Escherichia coli (rHBcAg) or purified from Dane particles. Similar results were obtained in other neutralization studies (8) .
Alternative anti-HBc assay formats have been devised, including a direct sandwich assay in which anti-HBc is captured by binding to rHBcAg on a solid phase and then * Corresponding author.
detected by using HBcAg labeled with 1251 or horseradish peroxidase (9) . These low-level anti-HBc reactives were also positive in this sandwich assay, indicating that an HBcAg binding substance may be detected regardless of assay format.
Chau et al. (2) and Weare et al. (18) have demonstrated that many of these specimens become nonreactive for antiHBc after treatment with reducing agent (sodium metabisulfite, 2-mercaptoethanol, or cysteine). They have purified this reductant-sensitive factor and identified it as an immunoglobulin M (IgM) or IgM-like molecule (11) . Sallberg and Magnius (12) , using an antibody capture format for detection of subclass-specific anti-HBc, found low levels of IgM or IgA anti-HBc or both and suggested that the presence of these subclasses in sera may result from the unspecific activation of immature B lymphocytes and may not be the result of previous exposure to HBV.
In this study, numerous specimens from blood banks and hospital and reference laboratories were tested for anti-HBc reactivity by using a microparticle enzyme immunoassay (EIA) (IMx Core) which was fully automated on the Abbott IMx instrument. The addition of a reducing agent, dithiothreitol (DTT), to the specimen significantly decreased the number of discrepant specimens reactive by anti-HBc assays but negative for other hepatitis B markers. DTT addition destroyed the reactivity of unspecific IgM anti-HBc in sera from individuals not previously exposed to HBV without significantly affecting the ability of the immunoassay to detect anti-HBc resulting from HBV infection. The TMx Core also showed improved within-run and between-run reproducibility and had sensitivity of better than 0. Carboxylated latex particles (0.1 to 0.3 ,um in diameter) (Seradyn, Indianapolis, Ind.) were coupled to DEAE-purified human anti-HBc (Abbott Laboratories) by using 1-ethyl-3,3-(dimethylaminopropyl)carbodiimide chemistry (10) .
After the unbound anti-HBc was washed away, the microparticles were overcoated with purified rHBcAg. DEAEpurified human anti-HBc (Abbott Laboratories) was coupled to alkaline phosphatase by using a heterobifunctional crosslinking reagent (N-hydroxy succinimide ester and maleimide) (19) .
In the first step of the TMx assay, a specimen diluent containing DTT is added. Microparticles coated with rHBcAg are then added to the reaction mixture. This mixture is transferred to the glass fiber matrix and anti-HBcalkaline phosphatase conjugate is added. Anti-HBc, if present in the specimen, blocks the binding of anti-HBcalkaline phosphatase conjugate. Finally, the substrate, methylumbelliferyl phosphate, is added, and a fluorescent signal is generated. This signal is inversely proportional to the amount of anti-HBc captured by the microparticles from the specimen.
TMx 8, 192 . The lMx assay showed sensitivity for each of the 10 specimens two-to fourfold greater than that of the EIA. When these data were plotted as S/CO versus dilution factor (Fig. 1) , all 10 specimens gave parallel dilution curves, demonstrating that endpoint titers can give a semiquantitative measure of anti-HBc concentration in a specimen.
Reproducibility. The lMx assay reproducibility was determined by using a panel of five specimens containing various concentrations of anti-HBc. The panel was run in duplicate in 80 separate runs on seven instruments. The within-run, between-run, and total variation ranged from 3.5 to 6.2, 2.3 to 6.2, and 3.7 to 6.8%, respectively.
Specificity. Five clinical sites tested 4,841 specimens in parallel with the TMx Core and EIA (Table 1 ). The following samples were included in the study: 2,371 serum samples and 541 plasma specimens from volunteer blood donors, 1,201 diagnostic specimens from hospital patients, 102 specimens from obstetrical and gynecological patients, 372 specimens from patients with known diseases other than hepatitis B, 92 HBsAg-positive specimens, and 162 specimens which had previously tested positive for anti-HBc. Overall agreement between the TMx and EIA was 99.1% (4,797 of 4,841).
Histograms comparing the TMx and EIA for 2,371 blood donor serum samples show that the EIA gave a significantly broader population distribution than the IMx (Fig. 2) . In this population, the population mean S/CO obtained in the TMx was 5.0 standard deviations from the cutoff, compared with 3.2 standard deviations for the EIA.
This tighter distribution in the IMx Core assay can be attributed to the addition of reducing agent, DTT, to the specimen, since lMx Core run without reducing agent shows a significant broadening of the population around the negative population mean (data not shown). Furthermore, pretreatment of the specimen with the reducing agent sodium metabisulfite prior to testing by the EIA also significantly shifts the negative population distribution away from the cutoff for these assays (2) .
Forty-four specimens gave discordant results between the IMx and EIA, 40 of which were resolved by further testing. Thirty-three of the 44 discordants were classified as reduc- tant-sensitive reactives in Corzyme and did not have any other hepatitis B marker (anti-HBs, HBsAg, IgM anti-HBc). These 32 specimens shifted from Corzyme reactive (S/CO ranging from 0.34 to 0.98) to nonreactive (S/CO ranging from 1.08 to 2.53) when Corzyme was run in the presence of reducing agent (Fig. 3) . Seven discordants were reactive only in the IMx assay because of improved sensitivity over Corzyme. All of these seven specimens were positive for other hepatitis B markers. One specimen was positive in the EIA and RIA but negative by IMx. This specimen was positive for HBsAg and negative for IgM anti-HBc and was unresolved. The three remaining discordants could not be resolved with follow-up testing either because of insufficient volume for further testing or because no other hepatitis B marker was detectable to indicate previous exposure to HBV.
In populations with low prevalence of anti-HBc, i.e., volunteer blood donors, in which the Corzyme reactive rate was 1.61%, 30% of all reactives resulted from the presence of a reduction-sensitive factor in sera (Table 1) . Most of these specimens had low-level Corzyme reactivity with an S/CO between 0.7 and 1.0, and these specimens became unreactive upon addition of reducing agent (Fig. 2) . In high-risk populations in which anti-HBc prevalence may range from 9.1 to 94%, a significantly lower percentage (7.6 to 3.9%) of Corzyme reactives is sensitive to reductant ( Table 1) .
Effect of reductant on IgG and IgM anti-HBc. To determine (12) . The overall prevalence of Corzyme-reactive individuals is strongly dependent upon the population tested; for example, 1.6% of random volunteer blood donors (47 of 2,912) were Corzyme reactive, compared with 9.1% of individuals tested in diagnostic or hospital settings (119 of 1,303). We found that 30% of the blood donors and 8% of the hospital population testing reactive for anti-HBc by Corzyme may not have been previously exposed to HBV ( Table 1 ). The overall prevalence of unspecific anti-HBc (defined as specimens whose reactivity in Corzyme is destroyed by treatment with reducing agent) was similar among these two groups, suggesting that both low-and high-risk populations may have similar rates of unspecific activation of immature B lymphocytes leading to detectable anti-HBc. We find that the reducing agent DTT, when added to the specimen during the IMx Core assay, significantly decreases the number of these unspecific reactive specimens.
Does the DTT treatment which destroys unspecific IgM anti-HBc significantly affect the measurement of specific anti-HBc arising from exposure to or infection with HBV? Although we demonstrate that the reductant has no effect on IgG anti-HBc reactivity in these assays, reductant destroys most of the reactivity of IgM anti-HBc purified from individuals having high titers of both IgM and IgG anti-HBc. We 
